New Paradigm for R&D Collaborations
 
 
Establish a Phase I Unit in Chang Gung Memorial Hospital, Linkou.
Co-developing pipeline small molecules, biologics, or device/diagnostics and sharing the IP with international academia or industrial partners.
Establish Academic-Industrial Collaboration Center under R&D Committee of CGMF to facilitate the process.
 
 
  Vision
 
 
Academia should assume a new role to not just for new targets discovery but also repurposing approved or abandoned drugs as PI-initiated trials.
New indications of approved drugs should be based on preclinical evidences.
Partnership between industry, government, academia, and non-profit organizations should be encouraged by universities, hospitals, and government (regulatory).
Intellectual properties (IPs) owned by international collaborative organizations or industrial partners can be developed or have add on value through clinical validation with CGU-CGMH. Likewise, IPs owned by CGU-CGMH can be translated through its collaborative partners.
Through the joint efforts of the researchers, molecular mechanisms can be discovered and targeted in prevention, diagnosis and therapy of human diseases.